Radiofrequency ablation of malignant liver tumors

Radiofrequency ablation of malignant liver tumors
复制标题

DOI:
10.1245/aso.2003.07.017
复制
发表时间:
2003-05-01
影响因子:
3.7
通讯作者:
Curley, SA
Curley, SA
中科院分区:
医学2区
文献类型:
--
作者:
Curley, SA

文献摘要

被引文献

相似文献

背景:射频消融(RFA)被用于治疗原发性和转移性肝脏肿瘤。肝RFA的适应症,治疗计划和局限性必须由外科医生治疗肝脏恶性肿瘤的定义和完善。方法:回顾使用RFA治疗不可切除的原发性和继发性肝脏恶性肿瘤在德克萨斯大学M。D.德克萨斯州休斯顿的安德森癌症中心和G.位于意大利那不勒斯的帕斯卡尔国家癌症研究所提供。描述了RFA后的患者选择、治疗方法、局部复发率和总体癌症复发率。结果:肝肿瘤的射频消融术可经皮、腹腔镜或开放手术进行。局部复发是经皮入路更常见的不完全治疗表现。与肝脏RFA相关的发病率和死亡率较低。如果进行细致的治疗计划,局部复发率很低。RFA可以安全地与大病灶的部分肝切除术相结合。RFA的原发性和转移性肝肿瘤的长期生存率尚未建立。结论:RFA的肝脏恶性肿瘤是一种安全和有前途的技术,产生凝固性坏死的不可切除的肝脏恶性肿瘤。这种治疗方式的经验还不够成熟,无法确定长期结果。
Background: Radiofrequency ablation (RFA) is being used to treat primary and metastatic liver tumors. The indications, treatment planning, and limitations of hepatic RFA must be defined and refined by surgeons treating hepatic malignancies.Methods: A review of the experience using RFA to treat unresectable primary and secondary hepatic malignancies at the University of Texas M. D. Anderson Cancer Center in Houston, Texas, and the G. Pascale National Cancer Institute in Naples, Italy, is provided. Patient selection, treatment approach, local recurrence rates, and overall cancer recurrence rates following RFA are described. The current literature on RFA of hepatic malignancies is reviewed.Results: RFA of hepatic tumors can be performed percutaneously, laparoscopically, or during an open surgical procedure. Incomplete treatment manifest as local recurrence is more common with a percutaneous approach. The morbidity and mortality rates associated with hepatic RFA are low. Local recurrence rates are low if meticulous treatment planning is performed. RFA can be combined safely with partial hepatic resection of large lesions. The long-term survival rates following RFA of primary and metastatic liver tumors have not yet been established.Conclusions: RFA of hepatic malignancies is a safe and promising technique to produce coagulative necrosis of unresectable hepatic malignancies. Experience with this treatment modality is not yet mature enough to establish long-term outcomes.